The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This non-systematic review of the literature summarizes the evidence that inflammation plays a major role in the psychopathology of schizophrenia and in the mechanisms that contribute to physical ill health that is commonly associated with schizophrenia. The impact of prenatal infections on the developing brain, the possible genetic link between the human lymphocyte antigen gene, inflammation, heart disease and diabetes, together with the increase in pro-inflammatory cytokines in the blood and cerebrospinal fluid provide convincing evidence that inflammation is a major factor in the pathology of this disorder. The changes in immune-related markers and specific neurotransmitters associated with the positive symptoms of schizophrenia are described. In addition, the possible mechanism whereby structural changes occur in the brain is associated with the neurotoxic effects of pro-inflammatory cytokines, together with the neurotoxic metabolites from the tryptophan–kynurenine pathway that is activated by pro-inflammatory cytokines, is also discussed. The role of effective antipsychotic drug treatment in attenuating the inflammatory response is described. However, evidence is limited regarding the causal connection between atypical antipsychotic drugs and the changes in glucose and lipid metabolism that could trigger the onset of physical ill health, including diabetes and heart disease. Indeed, there is evidence that there is a metabolic predisposition to diabetes in patients with schizophrenia that is exacerbated by obesity and thereby contributes to cardiovascular disease and other co-morbid illnesses. It is concluded that the effects of inflammatory mediators on the brain causally contribute to the pathology of schizophrenia and the ill health that accompanies the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor
Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P., & Vale, W. (1987) · Science · doi:10.1126/science.2821621 · Cited by 1,504 · cited 1×
“…(HPA) axis, an effect that is reflected in the increased response of patients with schizophrenia to any stressful stimulus (Sapolsky et al., 1987; Sapolsky, 2003; Whalley et al., 1989), even though there are reports mentioning hypoactive HPA axis (Hempel et al., 2010) or…”
BackgroundDe Souza, C. T., Araujo, E. P., Bordin, S., Ashimine, R., Zollner, R. L., Boschero, A. C., Saad, M. J. A., & Velloso, L. A. (2005) · Endocrinology · doi:10.1210/en.2004-1520 · Cited by 1,171
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Is schizophrenia a neurodevelopmental disorder?
Murray, R. M., & Lewis, S. W. (1987) · BMJ · doi:10.1136/bmj.295.6600.681 · Cited by 889
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“Moreover, IL-6 also has a nonimmunological and non-neurochemical role, such as inducing cellular insulin resistance in hepatocytes (Senn et al., 2002).”
BackgroundSteen, R. G., Mull, C., Mcclure, R., Hamer, R. M., & Lieberman, J. A. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.6.510 · Cited by 832 · cited 1×
“…be responsible for the selective neurodegenerative changes in areas such as the temporal gyrus, the volume of which has been shown to decrease before the occurrence of the first major schizophrenic episode (Chakos et al., 2005; Körschenhausen et al., 1996; Geuze et al., 2005; Steen et al., 2006).”
BackgroundCytokines and the Brain: Implications for Clinical Psychiatry
Kronfol, Z., & Remick, D. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.683 · Cited by 784 · cited 2×
“One possibility is that the changes in the endocrine and immune systems that are associated with neurodevelopmental defects sensitize the developing brain and therefore cause more permanent changes in the neurotransmitter networks in the mature brain (Kronfol and Remick, 2000).”
BackgroundCardiorespiratory Fitness and Adiposity as Mortality Predictors in Older Adults
Sui, X., LaMonte, M. J., Laditka, J. N., Hardin, J. W., Chase, N., Hooker, S. P., & Blair, S. N. (2007) · JAMA · doi:10.1001/jama.298.21.2507 · Cited by 640
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634 · cited 1×
“This area has been recently reviewed by De Hert et al. (2009).”
MethodIncreased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Cited by
The nature of relapse in schizophrenia
Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-50 · Cited by 478
Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
van Kesteren, C. F. M. G., Gremmels, H., de Witte, L. D., Hol, E. M., Van Gool, A. R., Falkai, P. G., Kahn, R. S., & Sommer, I. E. C. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.4 · Cited by 368
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339
Inflammation and the two-hit hypothesis of schizophrenia
Feigenson, K. A., Kusnecov, A. W., & Silverstein, S. M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 282
Severance, E. G., Yolken, R. H., & Eaton, W. W. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.027 · Cited by 253
Metadata
- Authors
- Leonard, B. E., Schwarz, M., & Myint, A. M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-04-02
- Volume
- 26
- Issue
- 5_suppl
- Pages
- 33-41
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2030806228
- Cited by
- 134
- References
- 17
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The metabolic syndrome in schizophrenia: is inflammation a contributing cause? https://app.cochat.ai/papers/10.1177/0269881111431622
- The paper
- Leonard, B. E., Schwarz, M., & Myint, A. M. (2012). The metabolic syndrome in schizophrenia: is inflammation a contributing cause? Journal of Psychopharmacology. https://doi.org/10.1177/0269881111431622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.